-

Metrion Biosciences Appoints Dr Benedetta Montagnini as Head of European Business Development

Expansion of European business development team supports next phase of growth for Metrion’s ion channel drug discovery services

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Dr Benedetta Montagnini as Head of European Business Development. Driven by the uptake of its ion channel discovery services, the appointment follows the recent creation of a Client Services team as Metrion expands its operations and enhanced drug discovery capabilities, internationally.

Based in Rome, Italy, Dr Montagnini will provide local support to Metrion’s existing client base across Europe and Israel, along with leading the development of new business opportunities in the ion channel field. With over 20 years experience working within the drug discovery services environment, Dr Montagnini was previously Business Development Manager at Eurofins Discovery and DiscoveRx and prior to that Account Manager for the Industrial BioProcessing Division at Invitrogen. She holds a Bachelor’s degree in Molecular Biology and a PhD Magna cum Laude in Biochemistry from Sapienza Università di Roma.

Dr Benedetta Montagnini, Head of European Business Development at Metrion Biosciences, commented: “Metrion’s continued growth substantiates its position as a leading provider of drug discovery research services for ion channel targets across a broad range of therapeutic areas. This reputation attracted me to the Company, and I am delighted to be joining the team at this point in its expansion. I look forward to working with both existing and new clients and supporting the community across Europe. I have a great respect for Metrion’s strong scientific focus for ion channel drug discovery and vision for the future development of its services”

Nick Foster, Chief Commercial Officer of Metrion Biosciences, said: “It is a pleasure to welcome Benedetta to the Metrion team. Engaging with and supporting our clients, locally and internationally, is Metrion’s top priority and this exciting development enables us to enhance our ability to provide local support in Europe. Benedetta’s appointment and the continuing expansion of our team of scientists, celebrates the Company’s success and gives us a strong footing for our future growth in these regions.”

ENDS

Contacts

Media contact:
Lily Jeffery
Zyme Communications
E-mail: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

Metrion Biosciences Limited


Release Versions

Contacts

Media contact:
Lily Jeffery
Zyme Communications
E-mail: lily.jeffery@zymecommunications.com
Tel: +44 (0)7891 477 378

More News From Metrion Biosciences Limited

Metrion Biosciences Launches Nav1.9 High-Throughput Screening Assay to Strengthen Screening Portfolio and Advance Research on New Medicines for Pain

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a global leader in ion channel services, today announced the launch of its validated, high-throughput NaV1.9 screening assay to advance discovery and development of novel pain therapeutics. Leveraging over a decade of electrophysiology expertise, the NaV1.9 assay, alongside Metrion’s unique combination of ion channel expertise, bespoke assays and pain researc...

Metrion Biosciences appoints Lee Patterson as CEO

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andre...

Metrion Biosciences Appoints Dr Chris Mathes as Chief Commercial Officer

CAMBRIDGE, England--(BUSINESS WIRE)--Metrion Biosciences Ltd (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Dr Chris Mathes, MBA, as Chief Commercial Officer (CCO). Chris will work alongside the Company’s expert leadership team to drive commercial strategy and lead global business development and marketing activities. Following completion of Metrion’s £3.7M equity financing in December 20231,...
Back to Newsroom